Arvinas, Inc. Common Stock ARVN
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T15:45:20.338Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T15:43:56.600087796Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-11T15:45:18.904397+00:00
Arvinas, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 6.12 | 65.8% | 10.9% | |||
| 25Δ | 6.20 | 62.2% | 9.9% | |||
| 30Δ | 6.27 | 58.7% | 9.0% | |||
| 35Δ | 6.35 | 55.2% | 8.1% | |||
| 40Δ | 6.43 | 51.7% | 7.2% | |||
| 45Δ | 6.51 | 48.2% | 6.2% | |||
| 50Δ | 6.59 | 44.7% | 5.3% | |||
| 55Δ | 6.66 | 41.2% | 4.4% | |||
| 60Δ | 6.72 | 302.8% | 18.4% | 6.74 | 37.7% | 3.5% |
| 65Δ | 6.32 | 316.5% | 15.9% | |||
| 70Δ | 5.93 | 323.7% | 13.3% | |||
| 75Δ | 5.54 | 304.2% | 10.0% | |||
| 80Δ | 5.15 | 284.7% | 6.8% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.12
- IV
- 65.8%
- B/E move
- 10.9%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.20
- IV
- 62.2%
- B/E move
- 9.9%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.27
- IV
- 58.7%
- B/E move
- 9.0%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.35
- IV
- 55.2%
- B/E move
- 8.1%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.43
- IV
- 51.7%
- B/E move
- 7.2%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.51
- IV
- 48.2%
- B/E move
- 6.2%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.59
- IV
- 44.7%
- B/E move
- 5.3%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.66
- IV
- 41.2%
- B/E move
- 4.4%
60Δ
- Pseudo strike
- 6.72
- IV
- 302.8%
- B/E move
- 18.4%
- Pseudo strike
- 6.74
- IV
- 37.7%
- B/E move
- 3.5%
65Δ
- Pseudo strike
- 6.32
- IV
- 316.5%
- B/E move
- 15.9%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 5.93
- IV
- 323.7%
- B/E move
- 13.3%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 5.54
- IV
- 304.2%
- B/E move
- 10.0%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 5.15
- IV
- 284.7%
- B/E move
- 6.8%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 88.98% | |
| 70.69% | |
| 76.59% | |
| 101.31% | |
| 106.76% | |
| 108.44% | |
| 96.78% | |
| 101.08% | |
| 93.14% | |
| 99.81% |
Biotechnology
ARWR
Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.
More →ASMB
Assembly Biosciences, Inc. is a clinical-stage biotechnology company in the United States. The company is headquartered in South San Francisco, California.
More →ASND
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
More →ATNM
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplantation (BMT) or a type of…
More →ATOS
Description unavailable
More →AUPH
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is…
More →